AMERICAN BIOGENETIC SCIENCES
NEGOTIATES LANDMARK ANTHRAX AND SMALLPOX VACCINE AGREEMENT
26, 2001, Moscow, Russia,
New York, USA - American Biogenetic Sciences, Inc.
has negotiated a ten-year agreement with the Ministry
of Health of the Russian Federation. The agreement
covers human vaccines for anthrax, smallpox, botulism
and other diseases. A second agreement with the Russian
Agricultural Academy extends ABSs rights for
livestock vaccines, including one for animal anthrax.
The agreements govern vaccine distribution to specified
global territories including North America, South
America, The European Community, and The Pacific Rim.
is a very significant partnership given recent events
in the United States and the imminent and real threat
of bio-terrorism, says ABSs, Chairman
and Chief Executive Officer, Alfred J. Roach. This
is just one example of how America and Russia can
work together to safeguard the health of people worldwide,
especially those who are most vulnerable to international
on the agreement, Professor Rem V. Petrov, D.Sc.,
Vice-President of the Russian Academy of Sciences
speaking on behalf of his colleagues, Professor G.
Onishenko, Deputy Minister of Health and Professor
G. Romanenko, President and Professor Earnst Lev,
Vice-President of the Agricultural Academy said, ABSs
mission was evaluated at the very highest level in
the Russian Ministry of Health and the Russian Academy
of Agriculture. They are now in a position to respond
to the heightened concern about the recent spate of
Anthrax attacks in the U.S. and other bio-terrorism
the terms of the agreements, ABS can immediately make
the vaccines available for evaluation. The smallpox
vaccine developed in Russia was used by the World
Health Organisation (WHO) in the 1970s during
the global eradication of smallpox.
Roach says the partnership came about largely as a
result of the ABS Global Scientific Network, an in-house
advisory council of scientists and academics in the
U.S., Ireland, Germany, Russia and China, which continues
to work on developing potential products and programs
aimed at diagnosing and treating important diseases
such as cardiovascular and neurological illnesses.
I am pleased that my nearly 15-year relationship
with the Russian scientific community has led to its
greatest dividend to date. My meetings with scientists
around the world have given me great faith that we
will find ways to deter and to eliminate both the
global threats of bio-terrorism and of incurable diseases,
developed superior vaccines in Russia that have proven
themselves highly effective, says Professor
Petrov, who is also a member of both ABSs Advisory
Board and Global Scientific Network. We look
forward to working with ABS to protect the USA and
its Allies from these potentially deadly pathogens,
Biogenetic Sciences, Inc., is based in Copiague, NY,
and researches and develops diagnostic tests for cardiopulmonary
conditions and infectious diseases, as well as for
new treatments for neurological disorders, including
epilepsy, migraine, mania, and Alzheimers disease.
As an innovative developer of biogenetic technologies
and compounds, ABS to date has been issued over 75
patents, both US and foreign, and there are over 100
in this release that are not strictly historical are
forward-looking statements within the
meaning of the Private Securities Litigation Reform
Act of 1995 and should be considered as subject to
various risks and uncertainties that could cause actual
results to differ materially from those anticipated.
details and a discussion of these risks and uncertainties,
see ABSs Securities and Exchange Commission
filings including its annual report or 10-K form.
more information, please contact:
For a complete analysis of the ABS pipeline
go to: /research.html.